Please try another search
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Name | Age | Since | Title |
---|---|---|---|
Norbert W. Bischofberger | 68 | 2018 | President, CEO & Director |
Myles Brown | - | - | Scientific Advisory Board Member |
Arie S. Belldegrun | 75 | 2017 | Independent Chairman of the Board |
Joshua A. Kazam | 47 | 2017 | Co-Founder & Director |
Angela Koehler | - | - | Scientific Advisory Board Member |
Robert N. Eisenman | - | - | Scientific Advisory Board Member |
Roger D. Dansey | 68 | 2023 | Independent Director |
Katherine Vega Stultz | 51 | 2023 | Independent Director |
David M. Tanen | 53 | 2017 | Secretary & Director |
Elena H. Ridloff | 44 | 2020 | Independent Director |
Owen N. Witte | 74 | - | Scientific Advisory Board Chairman |
Taiyin Yang | 70 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review